# CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

> **NCT05436093** · NA · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 15 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** 18F-FDG

## Key facts

- **NCT ID:** NCT05436093
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-23
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05436093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05436093, "CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05436093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*